 | Form 4 Filings | Insider Buys | Significant Buys | Penny Stocks Insider Buying | Insider Sales |
| Insider Buy Sell Ratios | Stock Options | Insider Trading Stock Screener | Insider Trading Graph View | Insider Watch |
Insider Trading - Akero Therapeutics Inc. (AKRO)
| | "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise" - Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2020-03-04 Sale | 2020-03-06 5:23 pm | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 45,950 | $23.76 | $1,091,608 | 3,150,019 (Indirect) | View |
| 2020-02-28 Sale | 2020-03-03 5:52 pm | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 21,798 | $22.63 | $493,310 | 3,195,969 (Indirect) | View |
| 2020-02-25 Sale | 2020-02-27 7:51 pm | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 5,904 | $22.8 | $134,635 | 3,227,767 (Indirect) | View |
| 2020-02-11 Sale | 2020-02-12 5:56 pm | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 10,026 | $27.07 | $271,399 | 3,233,671 (Indirect) | View |
| 2020-02-06 Sale | 2020-02-10 5:47 pm | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 6,102 | $27.03 | $164,955 | 3,233,697 (Indirect) | View |
| 2020-02-04 Sale | 2020-02-06 4:06 pm | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 82,339 | $25.77 | $2,121,726 | 3,239,799 (Indirect) | View |
| 2020-01-16 Sale | 2020-01-21 9:57 pm | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC 10% Owner | 59,532 | $20.87 | $1,242,403 | 3,092,698 (Indirect) | View |
| 2020-01-10 Sale | 2020-01-15 9:53 pm | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC 10% Owner | 50,837 | $20.04 | $1,018,571 | 3,152,230 (Indirect) | View |
| 2020-01-13 Sale | 2020-01-14 08:58 am | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 494,000 | $20.23 | $9,993,620 | 3,322,138 (Indirect) | View |
| 2020-01-08 Sale | 2020-01-10 4:06 pm | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 15,677 | $19.86 | $311,355 | 3,816,138 (Indirect) | View |
| 2020-01-07 Sale | 2020-01-09 8:11 pm | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC 10% Owner | 53,057 | $19.99 | $1,060,845 | 3,203,067 (Indirect) | View |
| 2020-01-06 Sale | 2020-01-08 4:10 pm | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 73,221 | $19.86 | $1,454,530 | 3,831,815 (Indirect) | View |
| 2020-01-02 Sale | 2020-01-06 8:59 pm | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC 10% Owner | 72,444 | $19.7 | $1,427,272 | 3,256,124 (Indirect) | View |
| 2020-01-02 Sale | 2020-01-06 4:07 pm | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 35,498 | $19.71 | $699,721 | 3,905,036 (Indirect) | View |
| 2019-12-31 Sale | 2020-01-03 4:13 pm | Akero Therapeutics Inc. | AKRO | venBio Global Strategic Fund II L.P. venBio Global Strategic GP II L.P. venBio Global Strategic GP II Ltd. Adelman Robert J GOODMAN COREY S 10% Owner | 14,324 | $23.96 | $343,259 | 3,940,534 (Indirect) | View |
| 2019-12-27 Sale(A) | 2019-12-31 7:11 pm | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. 10% Owner | 389,382 | $24.2 | $9,421,175 | 3,656,585 (Direct) | View |
| 2019-12-27 Sale | 2019-12-31 6:05 pm | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. 10% Owner | 389,382 | $24.2 | $9,421,175 | 3,656,585 (Direct) | View |
| 2019-12-20 Sale | 2019-12-26 8:59 pm | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. 10% Owner | 49,220 | $21.34 | $1,050,416 | 4,045,967 (Direct) | View |
| 2019-12-17 Sale | 2019-12-19 9:30 pm | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. 10% Owner | 9,671 | $19.56 | $189,197 | 4,095,187 (Direct) | View |
| 2019-06-24 Purchase | 2019-06-25 6:06 pm | Akero Therapeutics Inc. | AKRO | Bitterman Kevin Director | 270,000 | $16 | $4,320,000 | 505,099 (Indirect) | View |
| 2019-06-24 Purchase | 2019-06-25 6:06 pm | Akero Therapeutics Inc. | AKRO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI LLC Atlas Venture Associates XI L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC Atlas Venture Opportunity Fund I L.P. 10% Owner | 270,000 | $16 | $4,320,000 | 505,099 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2020-03-30 Exercise | 2020-04-01 6:52 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Graham G. Walmsley Director | 2,168 | $19.97 | 23,832 (Direct) | View |
| 2020-03-30 Exercise | 2020-04-01 6:52 pm | N/A 2029-11-07 | Akero Therapeutics Inc. | AKRO | Graham G. Walmsley Director | 2,168 | $19.97 | 23,832 (Direct) | View |
| 2020-03-13 Exercise | 2020-03-16 5:51 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Young Jonathan COO | 5,035 | $0.615 | 94,268 (Direct) | View |
| 2020-03-13 Exercise | 2020-03-16 5:51 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Young Jonathan COO | 6,082 | $0.615 | 94,268 (Direct) | View |
| 2020-03-13 Exercise | 2020-03-16 5:51 pm | N/A 2028-07-29 | Akero Therapeutics Inc. | AKRO | Young Jonathan COO | 5,035 | $0.615 | 94,268 (Direct) | View |
| 2020-03-13 Exercise | 2020-03-16 5:51 pm | N/A 2028-10-17 | Akero Therapeutics Inc. | AKRO | Young Jonathan COO | 6,082 | $0.615 | 94,268 (Direct) | View |
| 2020-03-12 Exercise | 2020-03-13 7:04 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 27,368 | $0.61 | 42,796 (Direct) | View |
| 2020-03-12 Exercise | 2020-03-13 7:04 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 22,656 | $0.61 | 42,796 (Direct) | View |
| 2020-03-12 Exercise | 2020-03-13 7:04 pm | N/A 2028-10-17 | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 27,368 | $0.61 | 42,796 (Direct) | View |
| 2020-03-12 Exercise | 2020-03-13 7:04 pm | N/A 2028-07-29 | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 22,656 | $0.61 | 42,796 (Direct) | View |
| 2020-02-07 Other | 2020-02-10 7:49 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Atlas Venture Opportunity Fund I L.P. 10% Owner | 50,510 | $0 | 404,079 (Indirect) | View |
| 2020-01-10 Exercise | 2020-01-10 7:39 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Young Jonathan COO | 17,621 | $0.615 | 100,350 (Direct) | View |
| 2020-01-10 Exercise | 2020-01-10 7:39 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Young Jonathan COO | 21,286 | $0.615 | 100,350 (Direct) | View |
| 2020-01-10 Exercise | 2020-01-10 7:39 pm | N/A 2028-07-29 | Akero Therapeutics Inc. | AKRO | Young Jonathan COO | 17,621 | $0.615 | 100,350 (Direct) | View |
| 2020-01-10 Exercise | 2020-01-10 7:39 pm | N/A 2028-10-17 | Akero Therapeutics Inc. | AKRO | Young Jonathan COO | 21,286 | $0.615 | 100,350 (Direct) | View |
| 2020-01-02 Other | 2020-01-06 8:59 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC 10% Owner | 684,143 | $0 | 3,256,124 (Indirect) | View |
| 2020-01-02 Other | 2020-01-06 8:59 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC 10% Owner | 13,683 | $0 | 3,256,124 (Indirect) | View |
| 2020-01-02 Other | 2020-01-06 8:59 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC 10% Owner | 13,683 | $0 | 3,256,124 (Indirect) | View |
| 2020-01-02 Other | 2020-01-06 8:59 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC 10% Owner | 11,803 | $0 | 3,256,124 (Indirect) | View |
| 2020-01-02 Other | 2020-01-06 8:59 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC 10% Owner | 11,803 | $0 | 3,256,124 (Indirect) | View |
| 2019-12-31 Option Award | 2020-01-03 6:16 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Cheng Andrew CEO | 1,025 | $18.87 | 326,314 (Direct) | View |
| 2019-12-31 Option Award | 2020-01-03 6:16 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 1,025 | $18.87 | 163,669 (Direct) | View |
| 2019-12-31 Option Award | 2020-01-03 6:15 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | White William Richard CFO | 1,025 | $18.87 | 1,025 (Direct) | View |
| 2019-12-31 Other | 2020-01-02 5:19 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Atlas Venture Fund XI L.P. 10% Owner | 242,883 | $0 | 2,706,412 (Indirect) | View |
| 2019-12-30 Acquisition | 2019-12-31 4:16 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Young Jonathan COO | 667 | $0 | 193,576 (Direct) | View |
| 2019-12-17 Other | 2019-12-19 5:34 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Atlas Venture Fund XI L.P. Atlas Venture Opportunity Fund I L.P. 10% Owner | 520,464 | $0 | 454,589 (Indirect) | View |
| 2019-12-17 Other | 2019-12-19 5:34 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Atlas Venture Fund XI L.P. Atlas Venture Opportunity Fund I L.P. 10% Owner | 50,510 | $0 | 454,589 (Indirect) | View |
| 2019-12-13 Option Award | 2019-12-13 9:08 pm | N/A 2029-12-12 | Akero Therapeutics Inc. | AKRO | Cheng Andrew CEO | 234,000 | $21.09 | 234,000 (Direct) | View |
| 2019-12-13 Option Award | 2019-12-13 9:07 pm | N/A 2029-12-12 | Akero Therapeutics Inc. | AKRO | White William Richard CFO | 85,000 | $21.09 | 85,000 (Direct) | View |
| 2019-12-13 Option Award | 2019-12-13 9:07 pm | N/A 2029-12-12 | Akero Therapeutics Inc. | AKRO | Young Jonathan COO | 85,000 | $21.09 | 85,000 (Direct) | View |
| 2019-12-13 Option Award | 2019-12-13 9:06 pm | N/A 2029-12-12 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 85,000 | $21.09 | 85,000 (Direct) | View |
| 2019-12-13 Option Award | 2019-12-13 9:06 pm | N/A 2029-12-12 | Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer | 85,000 | $21.09 | 85,000 (Direct) | View |
| 2019-11-08 Option Award | 2019-11-12 7:03 pm | N/A 2029-11-07 | Akero Therapeutics Inc. | AKRO | Harrison Seth Loring Director 10% Owner | 26,000 | $19.97 | 26,000 (Direct) | View |
| 2019-11-08 Option Award | 2019-11-12 7:02 pm | N/A 2029-11-07 | Akero Therapeutics Inc. | AKRO | Graham G. Walmsley Director | 26,000 | $19.97 | 26,000 (Direct) | View |
| 2019-11-08 Option Award | 2019-11-12 7:02 pm | N/A 2029-11-07 | Akero Therapeutics Inc. | AKRO | Bitterman Kevin Director | 26,000 | $19.97 | 26,000 (Direct) | View |
| 2019-06-24 Conversion | 2019-06-25 6:06 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Bitterman Kevin Director | 3,469,759 | $0 | 505,099 (Indirect) | View |
| 2019-06-24 Conversion | 2019-06-25 6:06 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Bitterman Kevin Director | 235,099 | $0 | 505,099 (Indirect) | View |
| 2019-06-24 Conversion | 2019-06-25 6:06 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Bitterman Kevin Director | 10,666,667 | $0 | 505,099 (Indirect) | View |
| 2019-06-24 Conversion | 2019-06-25 6:06 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Bitterman Kevin Director | 722,737 | $0 | 505,099 (Indirect) | View |
| 2019-06-24 Conversion | 2019-06-25 6:06 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI LLC Atlas Venture Associates XI L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC Atlas Venture Opportunity Fund I L.P. 10% Owner | 3,469,759 | $0 | 505,099 (Indirect) | View |
| 2019-06-24 Conversion | 2019-06-25 6:06 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI LLC Atlas Venture Associates XI L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC Atlas Venture Opportunity Fund I L.P. 10% Owner | 235,099 | $0 | 505,099 (Indirect) | View |
| 2019-06-24 Conversion | 2019-06-25 6:06 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI LLC Atlas Venture Associates XI L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC Atlas Venture Opportunity Fund I L.P. 10% Owner | 10,666,667 | $0 | 505,099 (Indirect) | View |
| 2019-06-24 Conversion | 2019-06-25 6:06 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI LLC Atlas Venture Associates XI L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC Atlas Venture Opportunity Fund I L.P. 10% Owner | 722,737 | $0 | 505,099 (Indirect) | View |